China vs United States: Statin use vs. average non-HDL cholesterol levels
China
3.3
in 2018
United States
3.3
in 2018
China rank
95th
United States rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- China
- United States
How they compare
China currently reports 3.3 against 3.3 in United States, a difference of 0.
Across all 39 years both countries report, United States has been ahead every year.
China ranks 95th and United States ranks 95th of 191 countries.
United States has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | China | United States | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.88 | 3.93 | 1.05 | United States |
| 1990s | 3.06 | 3.75 | 0.69 | United States |
| 2000s | 3.2 | 3.55 | 0.35 | United States |
| 2010s | 3.3 | 3.36 | 0.0556 | United States |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, China or United States?
- China, at 3.3 against 3.3 in United States as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between China and United States?
- 0, with China ahead.
- How many years of comparable data are there for China and United States?
- 39 years are reported by both, from 1980 to 2018.
- How do China and United States rank globally for statin use vs. average non-hdl cholesterol levels?
- China ranks 95th and United States ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.